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ABSTRACT
Introduction Neonatal sepsis outreaches all causes of 
neonatal mortality worldwide and remains a major societal 
burden in low and middle income countries. In addition to 
limited resources, endemic morbidities, such as malaria 
and prematurity, predispose neonates and infants to 
invasive infection by altering neonatal immune response 
to pathogens. Nevertheless, thoughtful epidemiological, 
diagnostic and immunological evaluation of neonatal 
sepsis and the impact of gestational malaria have never 
been performed.
Methods and analysis A prospective longitudinal 
multicentre follow- up of 580 infants from birth to 3 months 
of age in urban and suburban Benin will be performed. 
At delivery, and every other week, all children will be 
examined and clinically evaluated for occurrence of sepsis. 
At delivery, cord blood systematic analysis of selected 
plasma and transcriptomic biomarkers (procalcitonin, 
interleukin (IL)-6, IL-10, IP10, CD74 and CX3CR1) 
associated with sepsis pathophysiology will be evaluated 
in all live births as well as during the follow- up, and when 
sepsis will be suspected. In addition, whole blood response 
to selected innate stimuli and extensive peripheral blood 
mononuclear cells phenotypic characterisation will be 
performed. Reference intervals specific to sub- Saharan 
neonates will be determined from this cohort and 
biomarkers performances for neonatal sepsis diagnosis 
and prognosis tested.
Ethics and dissemination Ethical approval has been 
obtained from the Comité d’Ethique de la Recherche – 
Institut des Sciences Biomédicales Appliquées (CER- ISBA 
85 - 5 April 2016, extended on 3 February 2017). Results 
will be disseminated through international presentations 
at scientific meetings and publications in peer- reviewed 
journals.
Trial registration number  ClinicalTrials. gov registration 
number: NCT03780712.
INTRODUCTION
Sepsis remains the first cause of perinatal 
morbidity worldwide affecting more than 
3 million neonates every year.1 Nearly half 
of neonatal deaths in sub- Saharan Africa 
are due to sepsis.2 In addition to neonatal 
sepsis, sub- Saharan Africa and South Asia that 
encompass 52% of world global live births, 
have an overweighed proportion of prema-
turity, which represents 60% of all preterm 
births worldwide.3 4 Low- and middle- income 
countries (LMIC) are supporting most of 
these neonatal morbidities and the societal 
and economic impacts are high, hampering 
most initiatives that target promotion of 
neonatal and paediatric health.5 6 Among 
others factors associated with neonatal infec-
tion, frequent endemic parasitic infections 
Strengths and limitations of this study
 ► This prospective, multicentre study in a limited- 
resources environment aims to characterise value of 
neonatal sepsis diagnosis and prognosis biomarkers 
in a high- risk gestational malaria (GM) area.
 ► The identified biomarkers through this study could 
provide new diagnostic and prognostic tools to iden-
tify immunosuppressed newborns at risk of neonatal 
sepsis.
 ► Clinical and immunological phenotypes, and func-
tional characterisations of a population with high 
risk of neonatal sepsis brings new insight to under-
standing the clinical and immune consequences of 
GM.
 ► Lack of biological antenatal malaria documentation 
in the hospital arm may limit the extrapolation to the 
first and second trimester GM impact.
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such as malaria, toxoplasmosis and schistosomiasis affect 
fetal and perinatal growth and development. Its specific 
impact on early childhood immunity is recognised and 
may explain altered vaccination response as well as 
increased risk of infection.7–9 During gestational malaria 
(GM), the sequestration and cytoadhesion of infected 
red blood cells within intervillous space of the placenta 
will lead to local inflammatory responses and alteration 
of placental functions, and subsequently promote intra-
uterine growth restriction and prematurity.10 11 In addi-
tion, in utero exposure to Plasmodium falciparum antigens 
impacts the newborn immune development12 13 and is a 
risk factor predisposing to malaria and other infections 
during the first year of life.14 15
Understanding fetal immune maturation and more 
specifically during the last 3 months of pregnancy is a 
prerequisite to an accurate interpretation of neonatal 
response to infection.16 17 To respond to pathogens, 
newborns depend essentially on their innate immune 
system. The Toll- like receptors (TLRs) represent the first 
line of defence and play an important role in orchestrating 
regulatory and inflammatory responses to pathogens and 
in initiating specific T and B cell responses.17–19 Increased 
risk of early and late neonatal infection and impaired host 
response seen in premature infants is related to altered 
innate immune functions.20–22 Although the underlying 
immunological basis are not well studied, small for 
gestational age (SGA) is also a recognised risk factors of 
neonatal infections.23 24 Defective innate immunity seen 
in premature infants is strongly correlated with the extent 
of immaturity where extremely low birth weight infants 
(ie, <28 weeks of gestational age) have a merely absent 
innate immune response.21 This state of ‘innate’ immu-
nodepression, although potentially reversible, shares 
many similarities to ‘acquired’ immunodepression seen 
in critically ill and septic patients.25–27 Currently, the most 
robust and reproducible marker of immunodepression is 
the measurement of monocytic HLA- DR surface expres-
sion (mHLA- DR). Extended literature has correlated its 
level during the course of disease to 28 days mortality and 
occurrence of secondary infections.28 Recently, two tran-
scriptional biomarkers were shown to identify similarly 
those conditions. CD74, coding for the γ chain (Li chain) 
of class II CMH and CX3CR1, the fractalkine receptor, 
were shown to be associated with mortality and/or the 
occurrence of secondary infections.29 30 Currently, less 
data exist on mHLA- DR in neonates. Although not found 
in all series, mHLA- DR seems to be reduced in prema-
ture infants compared with term infants and predicts 
both early- onset neonatal sepsis (EONS) and late- onset 
neonatal sepsis (LONS) with an acceptable accuracy 
(receiver operating characteristic area under the curve 
0.78; 95% CI: 0.61 to 0.92).21 31 No data exist on the 
value of both CD74 and CX3CR1 transcripts for prog-
nostication of neonatal sepsis. However, current under-
standing of sepsis pathophysiology and, more specifically, 
sepsis- induced immunodepression, sustain the explo-
ration of this specific condition, particularly in patients 
where immunodepressed states are known to be part 
of the pathophysiology and impact severity. Exploring 
biomarkers for sepsis diagnosis and prognostication in 
neonates exposed to GM may prove to be particularly 
relevant. Both a better characterisation of the immuno-
depressed state encountered in those patients and opti-
misation of sepsis diagnosis could be expected by using 
combined biomarkers, mixing both sepsis diagnosis and 
immunosuppression identification.
RATIONALE OF THE STUDY
From a clinical perspective, increased incidence of 
neonatal sepsis, more specifically to Gram- negative 
bacteria, has been repetitively shown in sub- Saharan 
infants.32 Effect of GM and prematurity are well known 
factors associated with bacterial infection susceptibility.1 33 
Although several studies have shown that in utero P. falci-
parum exposure impairs the immune development of 
newborns,34–37 making them more likely to develop 
malaria and other infections in their first months of life,12 
no study has detailed its immunological impact so far. 
The increased risk of neonatal sepsis has significant collat-
eral consequences such sepsis overdiagnosis, overuse of 
broad- spectrum antibiotics and development of antibiotic 
resistance. In such clinical context, antibiotic stewardship 
is central but limited by the lack of accurate diagnostic 
tools. Use of biomarkers of neonatal sepsis in LMIC is 
limited not only by economic perspectives but also due 
to the lack of validation in those populations. Only few 
epidemiological data exploring those conditions exist, as 
large prospective study requires important clinical and 
financial support to overcome limited resources in LMIC.
From a biological perspective, both GM and prematu-
rity could have similar impact on the newborn’s immune 
system such as impaired TLRs and T regulatory cells 
responses explaining this increased susceptibility to infec-
tion.34 37–40 Those altered immune responses, similar to 
a state of immunodepression, may impact the accuracy 
of biomarkers for EONS. GM- induced and prematurity- 
induced immunodepression were partially characterised 
by immune functional assay (cytokines release after ex vivo 
Pathogens- Associated Molecular Patterns (PAMPs) stimu-
lation) and peripheral blood mononuclear cell (PBMC) 
phenotyping, but most underlying molecular mechanism 
still remains to be identified.38 Better characterisation of 
the state of immunosuppression may help in optimising 
neonatal sepsis diagnosis and management in addition to 
opening a potential avenue for immune stimulation and 
restoration of efficient response to pathogens.21
Hypothesis
To overcome the lack of epidemiological data on GM and 
neonatal sepsis as well as on infant’s immune response, 
the SEPSIS study propose to prospectively follow infants 
born in an urban and suburban malarial endemic area 
from the peripartum period to 3 months of age. Biolog-
ical biomarkers, PBMC phenotyping as well as immune 
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functional assays will be performed at delivery and during 
the follow- up. Reference values will be determined and 
correlation between the biological measurements and 
occurrence of clinical neonatal sepsis performed. To 
explain the increased susceptibility of infants with GM, 
we hypothesised that in utero exposure to P. falciparum 
antigens modifies the TLRs transcriptional response 
(specifically of the endotoxins recognition complex 
myeloid differentiation factor 2: TLR4) and the Treg and 
Breg function when exposed to Gram- negative bacteria, 
which would explain the state of immunodepression in 
their first month of life. Therefore, besides phenotypic 
and functional characterisation of the immune response, 
specific analysis of the molecular mechanisms triggering 
GM- mediated immunodepression will be investigated. 
The SEPSIS project will provide validated reference 
values for current and new biomarkers of sepsis and 
GM- induced immunosuppression in sub- Saharan Africa, 
and may open new perspective in global understanding 
of sepsis in immunosuppressed infants.
Aims and objectives
The primary objective of this study is to evaluate procal-
citonin (PCT) for neonatal sepsis diagnosis and evaluate 
CD74 and CX3CR1 to prognose neonatal sepsis in GM 
endemic area. The secondary objectives are:
 ► To evaluate markers association (interleukin (IL)-6, 
TNFα, IL-10, IP10) to improve diagnosis and prog-
nosis accuracy of PCT, and CD74 and CX3CR1.
 ► To characterise the epidemiology of neonatal sepsis in 
this population.
 ► To characterise the effect of GM on the evolution of 
the innate and adaptive immune profiles between 
birth and 3 months of life in infants.
 ► To evaluate the molecular effect of GM on innate 
immune response to PAMPs.
The results of this large translational project in sub- 
Saharan Africa, where malaria, prematurity/SGA and 
neonatal infections are major public health issues, will 
contribute:
 ► To better understand the consequences of prematu-
rity and GM on the neonatal immune system and the 
associated immunosuppression.
 ► To test the use of biomarkers (including immuno-
suppression biomarkers) to optimise diagnosis and 
severity assessments of neonatal sepsis in a population 
with GM- induced immunosuppression and obtain 
reference values in sub- Saharian Africa.
 ► To evaluate experimental ex vivo therapy to reverse 
GM- induced immunosuppression.
METHODS AND ANALYSIS
SEPSIS is a prospective longitudinal, multicentre observa-
tional study conducted in the Abomey- Calavi, Sô-Ava and 
Cotonou districts in South Benin (figure 1).
Study population
In this project, patients will be enrolled from (1) three 
suburban health centres (the suburban arm) in order 
to follow low- risk delivery and (2) three urban hospitals 
(the Hospital arm) in order to follow infants born from 
high- risk delivery. In both arms, only women living in the 
Abomey- Calavi region will be recruited to facilitate the 
follow- up and to work on infant from the same geograph-
ical area.
 ► The suburban arm aims to follow low- risk deliveries 
and includes a part of children born to mothers previ-
ously included in the RECIPAL cohort (that aims to 
Figure 1 Geographical location of the six study centres in the Sô-Ava, Abomey- Calavi and Cotonou districts in Benin.
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evaluate the impact of GM on the fetal growth).41 
In this study arm, out of 411 pregnant women, 273 
will be followed until delivery for the study. Because 
of a delay in the timing between both projects, only 
the last 160 newborn of the RECIPAL cohort will be 
enrolled. The expected frequency of GM and prema-
turity are 40% and 12%, respectively. This cohort will 
provide specimen from the child and information on 
mother’s pregnancy and newborn’s follow- up.
 ► The Hospital arm aims to follow children born to 
mothers with high risk of developing neonatal sepsis. 
All consecutive deliveries with any perinatal risk of 
infection were included in the study. Those perinatal 
risk factors were as follows: prematurity, prolonged 
ruptures of membranes (>18 hours), maternal fever 
and/or infection, fetal distress, neonatal resuscitation 
at delivery and multiple gestation. Children will be 
recruited at birth in three main university hospitals: 
Centre Hospitalier Universitaire de la Mère et de l’En-
fant Lagune (CHUMEL), Centre National Hospitalier 
Universitaire (CNHU) in Cotonou and the Centre 
Hospitalier Universitaire Zone Abomey Calavi / Sô 
Ava (CHU ZAC) in Calavi. Approximately 420 chil-
dren will be followed with the inclusion and exclusion 
criteria presented in figure 2.
 ► The study is coordinated by the Institut de Recherche 
Clinique du Bénin (IRCB).
All children from both arms will be followed clinically 
on a bimonthly base during the first 3 months of life. The 
length of the follow- up was decided as being the most 
risky period in terms of susceptibility to sepsis, neonatal 
mortality and the development period for the immune 
responses.17
The clinical follow- up of these children will be 
conducted during the first 12 weeks of life during home 
visits or in healthcare centres. Newborn from the hospital 
arm will also be followed in case of hospitalisation for 
EONS. We expected that hospitalised newborns will stay 
from 1 to 10 days at the hospital after birth before going 
back to their home. The follow- up will consist of sched-
uled home visits and unscheduled emergency visits if the 
infant is sick.
1. Newborns will have a full clinical examination by a 
trained nurse at birth and during home visits (Birth, 
Week (W)1, W2, W4, W6, W8, W10 and W12).
2. Blood samples will be obtained at birth (cord blood), 
then at W1, W4, W8 and W12.
3. All sick infants identified during systematic home or 
unscheduled visits will come for a visit to a healthcare 
centre, where additional blood sample will be ob-
tained. Unscheduled visits will be called emergency 
visits in the rest of the document.
4. Healthcare centres are only able to perform haemo-
gram and blood smear. All infants with suspected sepsis 
needing additional therapeutic and diagnostic workup 
will be referred to the reference hospitals where sepsis 
workup can be performed. According to the clinical 
symptoms, the paediatrician will ask for specific bac-
teriological analysis to confirm a suspected infection.
Definition and neonatal sepsis diagnosis
Neonatal sepsis diagnosis will be established by the local 
paediatrician based on the child clinical examination 
and initial workup including haemogram, C- reactive 
protein (CRP) and microbiological cultures (blood, cere-
bral fluids and urine). In the Hospital arm of the study, 
neonatal sepsis will be suspected in neonates with peri-
natal infectious risk factors, as previously described, and 
more than two of the following criteria being present: 
neutrophil count <7500/mm3 or >14 500/mm3, band 
form >1500/mm3, immature/total neutrophils ratio 
>0.16, platelets count <1 50 000/mm3 and CRP >10 mg/L. 
Suspected neonatal sepsis will be considered as clinical 
sepsis when the following clinical signs are associated: 
Figure 2 Schematic design of the sepsis study illustrating inclusion, planned biological analysis and follow- up time points.
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temperature irregularity; respiratory distress or apnoea; 
seizures, altered tonus, irritability or lethargy; vomiting, 
altered feeding pattern, ileus; skin perfusion alteration, 
haemodynamic signs (tachycardia, hypotension); hypo-
glycaemic/hyperglycaemic, hyperlactatemia or identifi-
cation of focal infection such as soft tissue infection or 
conjunctivitis. In the suburban arm, neonatal sepsis will 
be suspected if the child demonstrates clinical signs as 
mentioned. In such case, the child will be transferred to the 
hospital where further sepsis workup will be performed. 
Neonatal sepsis will be considered as EONS if occurring 
within the first 72 hours after delivery, and LONS there-
after. Neonatal sepsis diagnosis and subsequent manage-
ment will be left at the discretion of the paediatrician in 
charge of the child. All newborns with a clinical diagnosis 
of sepsis will be subsequently adjudicated by two indepen-
dent paediatricians (PT, ULT) and sorted into ‘presumed 
sepsis’ and ‘definite clinical sepsis’. In addition to the 
full medical file review, microbiological cultures results 
will be monitored. Parallel to microbiological culture, we 
will use the specific BioFire Filmarray panels for all posi-
tive blood culture (Blood Culture Identification (BCID) 
panel) and cerebrospinal fluids (meningitis/encephalitis 
panel). All studied biomarkers will be kept blinded to the 
adjudication. In parallel, neonatal risk assessment will 
be scored using the Neonatal Sepsis Trial Network grid 
and patients scored from 1 to 3.42 GM will be defined as 
a malaria infection during pregnancy or at delivery. For 
women in the suburban arm, malaria screening will be 
performed at each scheduled prenatal visit using a thick 
blood smear. Mothers from the Hospital arm will be 
screened only at the time of delivery. In this group, ante-
natal malaria will be established on the basis of mother’s 
anamnesis. For both study arms, placental blood smear 
and mother’s peripheral blood smear will be performed. 
The Lambaréné technique will be used to quantify para-
sitaemia with a detection threshold of five parasites per 
microlitre.43
Sample and clinical data collection
Clinical and biological (biobanking) data dedicated to 
this project will be gathered according to table 1.
Table 1 Clinical and biological data collection planning
Mother Birth W01 W02 W04 W06 W08 W10 W12 Emergency
Patients characteristics
  Inclusion/exclusion criteria x
  Consent form x
  Demography x x
  Reproductive and obstetric x
  Anthropometry x x x x x x x x x x
  Malaria in pregnancy x
  Clinical examination x x x x x x x x x x
  Temperature x x x x x x x x x x
  Pulse rate x x x x x x x x x
  Breathing rate x x x x x x x x x
  Breastfeeding and feeding x x x x x x x x x
  Description of hospital stay x
Biology
  Dry blood spot x x x x x x
  Blood smear x x x x x x
  Heparin tube sampling x x x x x x
  Haemoglobin x x x x x x
  TLRs stimulation x x x
  Plasma x x x x x x
  Procalcitonin x x x x x x
  PBMC x x x
  Paxgen tube sampling x x x x x x
  Stool sampling x x x x x x
  Placenta biopsy x
PBMC, peripheral blood mononuclear cell; TLR, toll- like receptor; W, weeks.
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For the various biological tests to be performed in 
this study, the sample collection will allow us to establish 
several types of biobanking:
1. Heparin plasma for the study of protein biomarkers.
2. Supernatant from unstimulated whole blood and ex 
vivo stimulated with TLR ligands for the quantitative 
evaluation of cytokines release.
3. Messenger RNA (mRNA) biobank extracted from cell 
pellet of unstimulated whole blood and blood stimu-
lated with TLR ligands, preserved in PAXgene (Qia-
gen, Hilden, Germany) for the study of gene tran-
scripts of TLRs and signalling pathways.
4. mRNA biobank to study transcriptomic host biomark-
ers (RNA will be extracted from whole blood collected 
in PAXgene tubes).
5. Biobanking of PBMCs isolated from cord blood and 
peripheral blood by gradient separation of Ficoll 
(Sigma, Darmstadt, Germany) density for the explora-
tion of Treg and Breg cells function.
Biomarkers measurements
This part of the study will consist of testing blood samples 
of the children from both arms to validate CX3CR1, CD74, 
IL-10, PCT, IP10, TNFα and IL-6. For transcriptomic 
biomarkers, after extraction of from whole blood using 
the QIAsymphony SP/AS automated system (Qiagen, 
Hilden, Germany) with the QIAsymphony PAXgene 
blood RNA kit (PreAnalytiX, Hombrechtikon, Switzer-
land), mRNA from CD74 and CX3CR1 will be quantified 
by quantitative PCR (Q- PCR) using CD74/HPRT1 and 
CX3CR1/HPRT1 prototype kits (bioMérieux, Marcy- 
l’Etoile, France) on an ABI7500 thermocycler (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). Protein 
biomarkers associated with immunosuppression and 
inflammation (PCT, IL-6, TNFα, IL-10, and IP10) will be 
measured in heparinised plasma using the multiplex Ella 
platform (ProteinSimple, San Jose, California, USA).
Dynamic immune profiles
Here, we plan to study the immune profile of the first 
3 months of age. Biological samples will be used to 
determine and study the transcriptional and functional 
profiles of the innate and adaptive immunity. We foresee 
the following analyses:
1. Ex vivo functionality of the innate response via TLRs 
stimulation. Whole blood stimulation with TLRs ag-
onists (LPS, FSL1, Pam3CSK4, Flagellin, PolyI:C, 
CPG- ODN, Imiquimod and Resiquimod) (Sigma, 
Darmstadt, Germany). Proinflammatory and anti- 
inflammatory cytokines/chemokine (IL-6, IL-10, 
TNFα) in supernatants (eBioscience, Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) and genes 
transcripts quantification by Q- PCR will be performed 
using a CFX90 thermocycler (Biorad, Hercules, 
California, USA). Analysis will be performed in select-
ed patients divided into four groups (GM and sepsis, 
no GM and sepsis, GM and no sepsis, no GM and no 
sepsis). Patients will be selected from both study arms.
2. Ex vivo functionality and phenotyping of Treg and 
Breg lymphocytes. Using flow cytometry (FACS Canto, 
Becton Dickinson, Franklin Lakes, New Jersey, USA), 
we will investigate different functional markers like 
the gut- homing α4β7 integrins, CD39 and CTLA4 im-
munosuppressive markers. Second, the frequencies of 
Treg and Breg producing intracytoplasmic IL-10 and 
TGFβ will be assessed in cord blood after mitogen or 
antigen ex vivo stimulation.44–48
Modulation of the host response against P. falciparum
In this part, we aim to design an ex vivo experimental 
model of co- culture assays to mimic a clinical situation 
of malaria and Gram- negative infections. The objective 
is to perform in vitro co- culture functional assays with 
various stimuli combinations (TLRs agonists and/or P. 
falciparum- schizonte extract) to highlight the mechanisms 
of endotoxins anergy observed in infants with GM.
Sample size and data analysis plan
To assess the accuracy of new biomarkers of sepsis (PCT) 
and immunosuppression (CD74 and CX3CR1): we esti-
mated that of the 400 children, 40 would get an infec-
tion (fever) within 7 days after birth and 189 would get an 
infection within 3 months of follow- up (W2 to W12) after 
birth. With an expected proportion of 75% infection in 
PCT+ and 25% in PCT– (knowing that the difference in 
proportions is probably even greater between the two 
groups), t68 subjects (34 in each group) will be required 
to reach a 99% power and risk of first kind of 5%, which 
shows that the size of this study (higher in both groups) 
will answer this question with a power reaching almost 
100%. Statistical analyses were performed using R software 
V.3.6.1. Numbers and frequency were used for categorical 
data and means (SD) or medians (IQR) for continuous 
data. Categorical variables were compared using the χ2 
test (or Fisher’s exact test for small expected numbers). 
The distribution of continuous data was compared using 
Student’s t- test (or the Mann- Whitney test when distri-
bution was not normal) if the outcome was two groups, 
and analysis of variance (or the Kruskal- Wallis test when 
distribution was not normal) if not. OR and 95% CI were 
assessed using logistic regression models. An adjustment 
to the p values (q value) was performed using False 
Discovery Rate (FDR) correction (Benjamini- Hochberg). 
The independent variables initially included in the model 
were those associated with the infection of the newborn 
or infant in univariate analysis with p<20% and a stepwise 
or backward procedure was applied to assess variables 
that were significantly and independently associated with 
the infection of the newborn or infant at 5% level. When 
the linearity hypothesis was not respected, the continuous 
variables were transformed into ordered data (clinically 
meaningful classes or median separation). To analyse 
the infection of the newborn or infant, we considered 
variables associated with the patient (history of maternal 
infections, gestational age, child’s age, birth weight, 
prematurity, GM, SGA and other risk factors) and/or 
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with the different biomarkers (PCT, CD74 and CX3CR1). 
All reported p values are two- sided and the significance 
threshold was set at <0.05. Other machine models 
(Random Forest, Decision Tree, Support Vector Machine 
and k- Nearest Neighbour) will be used to increase perfor-
mance. For this purpose, the data will be divided into two 




The protocol, information documents and consent forms 
for legal representatives received approval from the 
ethical committee (CER- ISBA) in Benin (Approval code: 
CER- ISBA 85 - 5 April 2016). An amendment has been 
filed to extend the study to a second hospital cohort. This 
amendment was approved on 3 February 2017). This 
study complies with the Declaration of Helsinki princi-
ples of Good Practice and the Nagoya protocol.
Informed consent
 ► The study investigator who identified the child and 
the parents of the child will read the information 
document aloud and give them full details in the 
event of any questions.
 ► If the child's parents are literate, the information 
will be administered in French, and consent will be 
given to one of the parents (father or mother) of the 
child for proofreading. After reading and answering 
any questions from parents, the consent form will be 
signed. One of the parents and the interviewer will 
complete and sign the form in duplicate. One copy 
will be given to the parents and the second copy will 
be placed in the master file of the study.
 ► If the child’s parents are illiterate, the information 
will be administered in the local language (Mainly, 
Fon, Toffin, Aizo or other). In addition, the informa-
tion document will be given to an impartial witness, 
independent of the investigation and previously 
identified by the parents themselves, who will act 
as a signatory witness. This person may be a parent 
or guardian. After the parents' questions have been 
answered, consent will be signed: one of the parents 
will put the fingerprint of the left index finger in place 
of the signature and the witness present throughout 
the parent information process will sign the consent 
to his turn. Finally, the investigator will complete and 
sign the consent. The form will be completed in two 
copies. The parents will keep a copy of the consent 
and the second copy will be kept in the master file of 
the study.
 ► The consents will be kept at the IRCB premises for 5 
years.
Safety of participants
This study includes no serious foreseeable risk to the 
health of the children involved. The only potential risk 
is related to blood sample collection (maximum total 
blood per sampling 1 mL/kg, collected over all time 
points). In cases where children develop sepsis requiring 
hospitalisation, all related costs will be supported by the 
investigators.
Study management
The study is coordinated by bioMérieux and a dedicated 
team composed from members of the entire consortium. 
The clinical trial was coordinated by the IRCB.
Data management and handling
For each patient, a paper Case Report Form (CRF) 
including sociodemographic, anthropometric, clin-
ical and paraclinical information will be completed by 
clinical assistants and healthcare providers. MS Access 
was used to gather all the data from this clinical study. 
RStudio V.1.1.383 (RStudio, Boston, Massachusetts, USA) 
will be used to perform the statistical analysis of data. All 
samples and initial processing of the biobanking will be 
performed at the IRCB. Subsequently, biobanking will 
either stay at the IRCB or be transferred to the Chris-
tophe Mérieux research centre in Grenoble, France, 
for further processing (CD74 and CX3CR1 Q- PCR; 
biomarkers dosing). Whole blood ex vivo stimulation will 
be transferred to the Institute of Integrative Biology of 
the Cell, Gif- sur- Yvette, France. Data set will be available 
from the IRCB.
Medical confidentiality
All the data collected will be pseudonymised and covered 
by medical confidentiality. To protect the participant’s 
confidentiality, samples will be de- identified. The inves-
tigator will ensure that confidentiality is maintained. 
Patients will only be identified by their initials and study 
number (ID code) on the observation books or on all 
other documents. These ID codes will be kept separately. 
Patient data, identified by the ID code will be stored sepa-
rately. The investigator will ensure the retention of the 
identification list of patients included in the study. This 
includes at least the first page of the CRF and the Access 
databases (Microsoft, Redmond, Washington, USA). All 
the CRFs will be kept in the IRCB premises for at least 
5 years in an air- conditioned container. As part of data 
processing, data consultation and data analysis performed 
in France, all patients at each site will be informed of the 
data processing procedure as well as their rights including 
the right of access to and the right of opposition to the 
transmission of the data.
Professional secrecy will be respected by all the persons 
participating in the conduct of this study. The manager, 
the investigator and all their collaborators undertake the 
responsibility to not transmit to a third party any of the 
confidential information obtained through this research, 
including information on the health status of the patients 
or about the current study.
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